SCHEMBL8936762

SCHEMBL8936762

CNC(=O)[C@@H](OCn1cnc2c(NCc3cccc(I)c3)ncnc21)C(O)CO

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 9/20 0.55
ADORA2A P29274 5/20 0.55
ADORA1 P30542 4/20 0.55
CYP3A4 P08684 2/20 0.54
MAPK1 P28482 2/20 0.54
CYP1A2 P05177 1/20 0.54
MAPT P10636 1/20 0.54
LMNA P02545 1/20 0.54
BLM P54132 1/20 0.54
PMP22 Q01453 1/20 0.54
CYP2D6 P10635 1/20 0.54
PKM P14618 1/20 0.54
TSHR P16473 1/20 0.54
NFKB1 P19838 1/20 0.54
ABCG2 Q9UNQ0 1/20 0.54
HTR2C P28335 1/20 0.54
ADORA2B P29275 1/20 0.54
HTR2B P41595 1/20 0.54
RXFP1 Q9HBX9 1/20 0.54
PPARD Q03181 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8936789 0.88 ADORA3 (0.57) ADORA3ADORA2AADORA1MAPK1CYP1A2
SCHEMBL3049180 0.78 ADORA3 (0.58) ADORA3ADORA2AADORA1ADORA2B
SCHEMBL3055654 0.78 ADORA3 (0.58) ADORA3ADORA2AADORA1ADORA2B
SCHEMBL29501856 0.78 ADORA3 (0.58) ADORA3ADORA2AADORA1ADORA2B
SCHEMBL29501809 0.76 ADORA3 (0.59) ADORA3ADORA2AADORA1ADORA2B
SCHEMBL29463995 0.75 ADORA3 (0.77) ADORA3ADORA2AADORA1CYP3A4MAPK1
SCHEMBL91115 0.72 CDK1 (0.55) ADORA2AADORA1
SCHEMBL29501881 0.71 CDK1 (0.73) ADORA3ADORA2AADORA1
SCHEMBL22349409 0.71 CDK1 (0.73) ADORA3ADORA2AADORA1
SCHEMBL3060342 0.71 ADORA3 (0.73) ADORA3ADORA2AADORA1CYP3A4MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188063-B2 A2A receptor agonists for the central nervous system; antiinflammatory agents; 2,7-disubstituted-5-amino-pyrazolo[4,3-e]-[1,2,4]-triazolo[1,5-c]pyrimidines, mefloquine, 8-(3-chlorostyryl)caffeine, 3,7,8-trisubstituted-1-propargyl-xanthines; 2,5-disubstituted-7-amino-[1,2,4]triazolo[1,5-a][1,3,5]triazines UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2012-05-29 US disclosed
US-20080262001-A1 a 4-{3-[6-amino-9-(5-ethylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid ester ADENOSINE THERAPEUTICS, LLC (US) 2008-10-23 US disclosed
US-20080064653-A1 USE OF ADENOSINE A2A MODULATORS TO TREAT SPINAL CORD INJURY UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2008-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064653-A1 USE OF ADENOSINE A2A MODULATORS TO TREAT SPINAL CORD INJURY ADORA2A, ADORA2B, ADORA3 ADORA3 3/4885ADORA2A 1/4885ADORA1 4/4885
US-20080262001-A1 a 4-{3-[6-amino-9-(5-ethylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid ester ADORA2A, ADORA3, ADORA2B ADORA3 2/4885ADORA2A 1/4885ADORA1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.